Lexaria Bioscience Corp. announced details of an 8-week animal study WEIGHT-A24-1 (the "Study") to examine diabetes and weight loss effects of DehydraTECH-processed glucagon-likeptide 1 ("GLP-1") drugs and DehydraTECH- processed cannabidiol, alone and in combination. The contract for the Study has been awarded to a third-party, Health Canada-licensed Canadian research laboratory.

Manufacturing of the compositions for the first 8 of the 12 arms of the Study has already been completed, and those arms will commence as soon as the testing laboratory is able to do so, expected to begin within 45 days. Detailed information of the 12 Study arms is as noted: Group 1: DehydraTECH-CBD (composition "A") Group 2: DehydraTECH -CBD (composition "B") Group 3: DehydraTECH theCBD (composition "C") Group 4: DehydraTECH,GLP-1 (re-formulated Rybelsus®? "E") Group 6: DehydraTECH.

Group 7: DehydraTech-GLP-1 (pure semaglutide "G") Group 8: DehydraTECH--GLP-1 (pure liraglutide "H") Group 9: Combination of one of E, F, or G and one of A, B, C, or D (TBD); Group 10: Combination of H and one of A, B., C, or D (T BD); Group 11: Vehicle (placebo) arm; Group 12: Positive control arm. Each arm of the Study will be dosed for an 8-week period following an acclimation period. These statements may be identified by words such as "anticipate," "if," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions.

Such forward-looking statements in this press release include, but are not limited to, statements by the company relating the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, should not place undue reliance on these forward-looking statements.

Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited To, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any manner or in the Company's postulated use of products.